A new framework for buying medicines to manage Haemophilia A came into force across the UK on 1 July. This will run initially for 24 months. This framework differs to those in the past as it has been divided into 4 categories reflecting the different sort of products available, these being plasma-derived FVIII , standard half-life recombinant FVIII (4 products), enhanced half-life FVIII (3 products), and other haemophilia A treatments (1 product, Emicizumab.)
This means there is potentially a wider choice of treatments available for people that can be offered by your centre. You may find your centre will proactively contact you to discuss any possible changes to your treatment to something which might be better or more convenient for you. It is important that you are given the opportunity to discuss fully any changes with your centre, what this means for you and ensure you are happy with the final decision. If you have any questions, please speak to your haemophilia centre clinical team.
You can find information on different products in our factsheet section.
You can find more detailed information from the EHC novel treatments periodic review.